Feedback
Settings

Settings

Goto Application

112,123 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(UGQMRVRMYYASKQ-KQYNXXCUSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 11,213
1.WO/2025/119346ANP-DEPENDENT ANTIBODIES
WO - 12.06.2025
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
 Appl.No PCT/CN2024/137508 Applicant LANOVA MEDICINES LIMITED Inventor LI, Runsheng
Provided are antibodies capable of binding an antigen in an adenine nucleotide-dependent manner. Examples of adenine nucleotides include ATP, ADP and AMP, which are frequently present in tumor microenvironment at much higher concentrations in normal tissues. Such antibodies, if designed to target a tumor associated antigen or immune checkpoint molecule, can target tumor tissues more specifically than conventionally antibodies and thus have improved therapeutic index.
2.WO/2025/122721CHIMERIC PROTEINS AND USES THEREOF
WO - 12.06.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/US2024/058632 Applicant SHATTUCK LABS, INC. Inventor SCHREIBER, Taylor
The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
3.WO/2025/122916GENE EDITED POTATO PLANTS WITH IMPROVED HAPLOTYPES
WO - 12.06.2025
Int.Class A01H 6/82
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
HNEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
6Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
82Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
 Appl.No PCT/US2024/058948 Applicant OHALO GENETICS, INC. Inventor WARD, Judson Arthur
The disclosure herein discloses potato varieties with unique haplotypes that allow for the expression of improved cold storage in potatoes through potatoes with one or more the unique haplotypes to allow for improved ratios of reducing sugars and non-reducing sugars and/or reduced acrylamide in a processed potato product compared to that obtained from a control plant. This improved cold storage allows for improved chip lightness scores in the potatoes with these unique haplotypes.
4.WO/2025/122946ZIKA VIRUSES AND USES THEREOF
WO - 12.06.2025
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
 Appl.No PCT/US2024/058992 Applicant ROVIN, Richard, A. Inventor ROVIN, Richard, A.
Provided herein are methods of treating a cancer (e g., a glioblastoma, a breast cancer, or a melanoma) in a subject in need thereof. The methods comprise administering to the subject a zika virus, wherein the zika virus comprises a nucleotide sequence at least 99.6% identical with the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:2.
5.WO/2025/120097RNA-BASED STRATEGIES FOR DENDRITIC CELL REPROGRAMMING AND USES THEREOF
WO - 12.06.2025
Int.Class C12N 5/0784
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0784Dendritic cells; Progenitors thereof
 Appl.No PCT/EP2024/084945 Applicant ASGARD THERAPEUTICS AB Inventor ROSA, Fábio Alexandre Fiúza
The present invention relates to compositions comprising RNAs, uses thereof, and RNA-based gene expression methods for reprogramming cells to type 1 conventional dendritic cells or antigen-presenting cells. The invention further relates to cells, reprogrammed cells, and uses thereof.
6.WO/2025/119162METAPNEUMOVIRUS (MPV) VACCINE
WO - 12.06.2025
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
 Appl.No PCT/CN2024/136380 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided is a metapneumovirus (MPV) vaccine. Specifically, provided is a nucleic acid comprising a polynucleotide for encoding a mutant of an MPV F protein, compared with a wild-type MPV F protein, the mutant comprises a disulfide bond mutation.
7.WO/2025/122177EXTRACELLULAR VESICLES FOR THERAPY
WO - 12.06.2025
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
 Appl.No PCT/US2024/016447 Applicant LEKSUM LLC Inventor LARSSON, Lars
This disclosure provides a secretion centric therapy to overcome muscle wasting. Provided are mesenchymal stem cell secretion-based therapies to overcome muscle wasting due to: old age; as a consequence of immobilization (e.g., mobility restricted or paralytics administered); due to use of ventilators (e.g., in an ICU or long-term immobilization); in microgravity during long space flights; or, resulting from drug side effects (e.g., the use of weight loss drugs, chemotherapies, etc.). This disclosure further provides methods and compositions for modulating, including regulating or altering, the structure and function of diaphragm muscle cells and/or diaphragm muscle fibers in particular, and skeletal muscle in general. In certain embodiments extracellular vesicles are applied to patients affected by muscle wasting.
8.WO/2025/122628CIRCULARIZED RNAS AND METHODS OF MAKING THE SAME
WO - 12.06.2025
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No PCT/US2024/058479 Applicant HELIX NANOTECHNOLOGIES INC Inventor SAUCEDA, Arianna Lizeth Lopez
The present disclosure provides methods of circularizing RNA using RNA ligase. The present disclosure also provides polyribonucleotides that can be useful in such methods. Such polyribonucleotides can comprise a 5' end comprising a 5'- most nucleotide, a 3' end comprising a 3'- most nucleotide, a first hybridization region and a second hybridization region, wherein the ribonucleotide sequence of the second hybridization region is a reverse complement of the ribonucleotide sequence of the first hybridization region.
9.WO/2025/122824MULTIVALENT ANTIBODY CONSTRUCTS FOR TARGETING PROSTATE CANCER CELLS
WO - 12.06.2025
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
 Appl.No PCT/US2024/058800 Applicant NUTCRACKER THERAPEUTICS, INC. Inventor BANDI, Srinivasa
Disclosed are multispecific antibody constructs, and polynucleotides encoding for same, the proteins and antibody constructs being useful for the treatment of prostate cancer. The disclosed proteins and antibody constructs comprise at least one antigen binding domain that specifically binds to at least one prostate cancer cell specific antigen. The disclosed proteins and antibody constructs may further comprise at least one binding domain that specifically binds to a T-cell specific antigen, which may be used to form a multispecific T-cell engager molecule useful for the treatment of prostate cancer. Further disclosed are methods of making and using the disclosed compositions.
10.WO/2025/122419PLANT REGULATORY ELEMENTS AND USES THEREOF
WO - 12.06.2025
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
 Appl.No PCT/US2024/058062 Applicant MONSANTO TECHNOLOGY LLC Inventor DAVIS, Ian W.
The disclosure provides novel synthetic small nuclear RNA (snRNA) promoters which are useful for CRISPR-mediated targeted gene modifications in plants. The disclosure also provides methods and compositions for use for the snRNA promoters driving expression of guide RNAs and non-coding RNAs for development of plants and plant cells comprising modified genomes.
# -